Quest PharmaTech Inc. (QPTFF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 1.59 means the share price is 1.59 times one year of earnings per share. Market cap $5.07M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerQuest PharmaTech Inc. (QPTFF) trades at $0.03. Quest PharmaTech Inc. is a pharmaceutical company focused on developing antibody-based immunotherapeutic products for cancer treatment. Market cap: $5.07M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for QPTFF: QPTFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Quest PharmaTech Inc. (QPTFF) Healthcare & Pipeline Overview
Quest PharmaTech Inc., a Canadian biotechnology company, specializes in developing immunotherapeutic products, primarily focused on antibody-based cancer therapies. Their lead candidate, Mab AR 9.6, and other assets like Oregovomab, target specific cancer markers. The company also explores transdermal delivery technologies for dermatology and wound healing applications.
What Is the Investment Thesis for QPTFF?
The company's lead product candidate, Mab AR 9.6, holds promise as a targeted cancer therapy, but its clinical development is still in early stages. Successful completion of clinical trials and regulatory approval are critical value drivers. The company's market capitalization of $5.07M reflects its early-stage nature and the inherent uncertainties associated with drug development. A potential catalyst is the advancement of Mab AR 9.6 through clinical trials, with positive data readouts potentially driving significant stock appreciation. The negative P/E ratio of -8.65 indicates that the company is currently not profitable, highlighting the reliance on future product commercialization for revenue generation. Key risks include clinical trial failures, regulatory hurdles, and the need for additional financing to support ongoing research and development activities.
Based on FMP financials and quantitative analysis
QPTFF Key Highlights
Lead product candidate Mab AR 9.6 targets truncated O-glycan on MUC16 for cancer therapy.
- Oregovomab, an anti-CA-125 antibody, has completed Phase II clinical trial for ovarian cancer treatment.
- Developing immunotherapy products for pancreatic cancer.
- Exploring proprietary transdermal delivery technologies for dermatology and wound healing.
- Market capitalization of $5.07M reflects its early-stage nature and the inherent uncertainties associated with drug development.
Who Are QPTFF's Competitors?
QPTFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.43 | 0.00% | $29.2M | — |
| HMTXF Hemostemix Inc. | $0.03 | 0.00% | $5.64M | — |
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QPTFF's Key Strengths?
Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Lead product candidate Mab AR 9.6 shows promise.
What Are QPTFF's Weaknesses?
Early-stage development company with limited revenue.
- Reliance on successful clinical trials and regulatory approvals.
- High cash burn rate and need for additional financing.
- Limited commercialization experience.
What Could Drive QPTFF Stock Higher?
Clinical trial results for Mab AR 9.6.
- Potential partnerships or collaborations with pharmaceutical companies.
- Development of new immunotherapy products for pancreatic cancer.
What Are the Key Risks for QPTFF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- High cash burn rate and need for additional financing.
- Intellectual property challenges.
What Are the Growth Opportunities for QPTFF?
- Advancement of Mab AR 9.6: The successful advancement of Mab AR 9.6 through clinical trials represents a significant growth opportunity for Quest PharmaTech. Positive clinical data could lead to regulatory approval and commercialization, potentially generating substantial revenue. The timeline for commercialization depends on the successful completion of clinical trials, with potential launch within 5-7 years, pending regulatory approvals.
- Expansion of Immunotherapy Pipeline: Quest PharmaTech has the opportunity to expand its immunotherapy pipeline beyond Mab AR 9.6 and Oregovomab. Developing new antibody-based therapies targeting different cancer markers could broaden the company's addressable market and reduce its reliance on a single product. The global immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other immunotherapeutic approaches. The timeline for developing new immunotherapy products typically involves several years of preclinical research and clinical trials.
- Development of Transdermal Delivery Technologies: Quest PharmaTech's proprietary transdermal delivery technologies offer a growth opportunity in the dermatology and wound healing markets. Developing skin-penetrating active molecules for cosmetic and pharmaceutical applications could generate revenue streams outside of cancer therapeutics. The transdermal drug delivery market is projected to grow significantly, driven by the increasing demand for non-invasive drug delivery methods. The timeline for commercializing transdermal products is typically shorter than that for cancer therapeutics, with potential launch within 2-3 years.
- Strategic Partnerships and Collaborations: Quest PharmaTech can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its products. Partnering with established players can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly relying on collaborations to drive innovation and expand product portfolios. The timeline for establishing partnerships can vary depending on the specific opportunity and the interests of potential partners.
- Expansion into New Geographic Markets: Quest PharmaTech can explore opportunities to expand its geographic reach beyond its current focus. Entering new markets, such as Europe and Asia, could increase the company's potential customer base and revenue streams. The global pharmaceutical market is highly fragmented, with significant growth opportunities in emerging markets. The timeline for entering new geographic markets depends on regulatory approvals and the establishment of distribution networks.
What Are QPTFF's Competitive Advantages?
- Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Intellectual property protection through patents and trade secrets.
What Does QPTFF Do?
Quest PharmaTech Inc., headquartered in Edmonton, Canada, is a pharmaceutical company dedicated to the development of innovative antibody-based immunotherapeutic products for the treatment of cancer. The company's origins lie in the pursuit of targeted cancer therapies, leveraging its expertise in antibody engineering and drug delivery systems. Quest PharmaTech's lead product candidate is Mab AR 9.6, a monoclonal antibody targeting truncated O-glycan on MUC16, a marker highly expressed in various cancers. This targeted approach aims to deliver therapeutic payloads directly to cancer cells, minimizing off-target effects. In addition to Mab AR 9.6, Quest PharmaTech's portfolio includes Oregovomab, an anti-CA-125 antibody that has completed Phase II clinical trials for the treatment of ovarian cancer. The company is also involved in developing immunotherapy products for pancreatic cancer. Beyond its core focus on cancer therapeutics, Quest PharmaTech is exploring the application of its proprietary transdermal delivery technologies in dermatology and wound healing. This includes the development of skin-penetrating active molecules for cosmetic and pharmaceutical applications. The company also investigates combinatorial immunotherapeutic products that combine monoclonal antibodies of the immunoglobulin G and E classes for enhanced cancer treatment efficacy. Quest PharmaTech operates in the highly competitive biotechnology landscape, striving to advance its pipeline of innovative therapies and improve outcomes for cancer patients.
What Products and Services Does QPTFF Offer?
- Develop antibody-based immunotherapeutic products for cancer treatment.
- Focus on targeted cancer therapy applications.
- Offer Oregovomab, an anti-CA-125 antibody, for ovarian cancer treatment.
- Develop immunotherapy products for pancreatic cancer.
- Utilize transdermal delivery technologies for dermatology and wound healing.
- Create skin-penetrating active molecules for cosmetic and pharmaceutical use.
- Develop combinatorial immunotherapeutic products for cancer treatment.
How Does QPTFF Make Money?
- Develop and license antibody-based immunotherapeutic technologies.
- Conduct research and development to create new cancer therapies.
- Out-license or partner for commercialization of developed products.
- Generate revenue through licensing fees, milestone payments, and royalties.
What Industry Does QPTFF Operate In?
Quest PharmaTech Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The company focuses on the development of immunotherapeutic products for cancer, a market driven by the increasing prevalence of cancer and the growing demand for targeted therapies. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms, all vying for market share in the oncology space. Quest PharmaTech's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs and differentiate itself from competitors.
Who Are QPTFF's Key Customers?
- Pharmaceutical companies seeking to in-license novel cancer therapies.
- Biotechnology companies interested in partnering for drug development.
- Patients with cancer who may benefit from new treatment options.
- Dermatology and cosmetic companies interested in transdermal delivery technologies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Quest PharmaTech Inc. stands at 17.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.1%, showing how much profit it generates from its asset base. QPTFF trades at a trailing price-to-earnings ratio of 1.59, below the Healthcare sector average of ~21.70x. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 64.4%, the inverse of the P/E and a quick read on earnings relative to price.
Quest PharmaTech Inc. (QPTFF) Valuation Context
Valued at $5.07M, QPTFF is classified as a micro-cap stock.
Company Profile
Quest PharmaTech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Edmonton, Canada.
Financial Health
Quest PharmaTech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.03 places it in the grey zone, a middle ground that warrants monitoring.
QPTFF Financials
Bull Case vs Bear Case
Bull Case
- Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Lead product candidate Mab AR 9.6 shows promise.
Bear Case
- Early-stage development company with limited revenue.
- Reliance on successful clinical trials and regulatory approvals.
- High cash burn rate and need for additional financing.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QPTFF Latest News
No recent news available for QPTFF.
QPTFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for QPTFF.
Price Targets
Wall Street price target analysis for QPTFF.
QPTFF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for QPTFF; grades run from A+ (80-100) to F (below 30).
Leadership: Ragupathy Madiyalakan
CEO
Ragupathy Madiyalakan serves as the CEO of Quest PharmaTech Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions in various companies, overseeing research and development activities, clinical trials, and regulatory affairs. Madiyalakan's expertise spans multiple therapeutic areas, including oncology and dermatology. He is committed to advancing Quest PharmaTech's pipeline of innovative therapies and improving outcomes for patients.
Track Record: Under Ragupathy Madiyalakan's leadership, Quest PharmaTech has focused on advancing its lead product candidate, Mab AR 9.6, through preclinical and clinical development. He has also overseen the expansion of the company's immunotherapy pipeline and the exploration of transdermal delivery technologies. Key milestones include the completion of Phase II clinical trials for Oregovomab and the establishment of strategic partnerships to support research and development activities.
QPTFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quest PharmaTech Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Potential for delisting or trading suspensions.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other tier companies may have difficulty raising capital.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Development of antibody-based immunotherapeutic products for cancer treatment.
- Focus on targeted cancer therapy applications.
- Lead product candidate Mab AR 9.6 shows promise.
Quest PharmaTech Inc. Healthcare Stock: Key Questions Answered
Is QPTFF a good stock to buy?
Stock Expert AI does not rate QPTFF buy, sell or hold. Quest PharmaTech Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the QPTFF stock price today?
The last price recorded on this page for Quest PharmaTech Inc. (QPTFF) is $0.03, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for QPTFF?
The main risks for Quest PharmaTech Inc. include the inherent uncertainties associated with drug development, such as clinical trial failures and regulatory hurdles.
What are the key factors to evaluate for QPTFF?
Evaluate QPTFF on fundamentals, analyst consensus, and risk factors. P/E: 1.59x. Lead product candidate Mab AR 9.6 targets truncated O-glycan on MUC16 for cancer therapy. Not financial advice.
How frequently does QPTFF data refresh on this page?
QPTFF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven QPTFF's recent stock price performance?
Quest PharmaTech Inc. (QPTFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary antibody-based immunotherapeutic technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QPTFF overvalued or undervalued right now?
Quest PharmaTech Inc. (QPTFF) trades at 1.59x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QPTFF before investing?
Before investing in Quest PharmaTech Inc. (QPTFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be readily available or up-to-date.